Desperate hope: single patient gets custom RNA therapy for returning bone cancer

NCT ID NCT07560709

NO_LONGER_AVAILABLE Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study provided a single patient with recurrent osteosarcoma (a type of bone cancer) access to a personalized treatment made from their own tumor's genetic material. The therapy, called RNA-loaded lipid particles (RNA-LPs), was given intravenously to try to control the cancer. Because it was a one-patient expanded access program, it does not provide broad evidence of safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized RNA-loaded lipid particles (RNA-LPs)
What this could lead to: If it works, this could point toward a treatment for recurrent osteosarcoma that uses the patient's own tumor material to target cancer cells.
What could go wrong: This is a single-patient expanded access protocol, not a formal trial, so results may not apply to others. The treatment is experimental and may not slow disease progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT OSTEOSARCOMA

Contacts and locations

Locations

University of Florida Health

Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.